Natera, Inc. (NASDAQ:NTRA) Given Average Rating of “Buy” by Brokerages

Natera, Inc. (NASDAQ:NTRA) has been given a consensus recommendation of “Buy” by the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $120.07.

A number of equities research analysts have recently issued reports on NTRA shares. Robert W. Baird boosted their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Canaccord Genuity Group upped their price target on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, UBS Group dropped their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 499 shares of Natera stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the sale, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at approximately $8,314,693.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Solomon Moshkevich sold 549 shares of Natera stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $57,732.84. Following the sale, the insider now directly owns 113,637 shares of the company’s stock, valued at $11,950,066.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total transaction of $53,592.60. Following the sale, the chief financial officer now directly owns 77,418 shares in the company, valued at $8,314,693.20. The disclosure for this sale can be found here. Insiders sold a total of 93,921 shares of company stock worth $10,551,281 in the last ninety days. 7.60% of the stock is owned by insiders.

Institutional Trading of Natera

Several institutional investors have recently modified their holdings of NTRA. Itau Unibanco Holding S.A. acquired a new position in shares of Natera in the 2nd quarter worth approximately $28,000. Principal Securities Inc. bought a new position in Natera during the fourth quarter worth $32,000. Quarry LP lifted its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the period. GAMMA Investing LLC boosted its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares during the last quarter. Finally, YHB Investment Advisors Inc. acquired a new stake in Natera during the 1st quarter worth about $36,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Down 0.4 %

NTRA opened at $123.08 on Friday. The stock’s fifty day simple moving average is $114.84 and its 200 day simple moving average is $106.00. Natera has a 1-year low of $36.90 and a 1-year high of $132.01. The stock has a market cap of $15.11 billion, a PE ratio of -39.45 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue was up 58.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.97) earnings per share. As a group, research analysts expect that Natera will post -1.96 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.